Advertisement
Screener

Inhibikase Therapeutics, Inc. (IKT) Public Float

2.8 / 5 stars · 68/120 Roast Me

Inhibikase Therapeutics, Inc. Public Float

Inhibikase Therapeutics, Inc. (IKT) had Public Float of $127.30 million as of 2025-06-30, per its 10-K filed 2026-03-26.

Financial Statements › Notes › Cover Page

dei:EntityPublicFloat · last filed 2026-03-26

  • 2025-06-30: Entity Public Float $127.30M.
  • 2024-06-28: Entity Public Float $7.70M.
  • 2023-06-30: Entity Public Float $19.10M.
  • 2022-06-30: Entity Public Float $18.70M.
Period endEntity Public Float
2025-06-30$127.30M
10-K · filed 2026-03-26
2024-06-28$7.70M
10-K/A · filed 2025-04-25
2023-06-30$19.10M
10-K · filed 2024-03-27
2022-06-30$18.70M
10-K/A · filed 2023-10-16
2021-06-30$51.40M
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34